The 35 references in paper О. Шахматов О., Е. Панченко П., О. Шахматова О., Е. Панченко П. (2015) “АПИКСАБАН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ” / spz:neicon:aterotromboz:y:2015:i:1:p:52-64

1
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke,1991; 22(8): 983–8.
(check this in PDF content)
2
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patientswith atrial fibrillation. N Engl J Med, 2009; 361(12): 1139–51.
(check this in PDF content)
3
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med, 2011; 365(10): 883–91.
(check this in PDF content)
4
Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2011; 365: 981–992.
(check this in PDF content)
5
Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart
(check this in PDF content)
6
Disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thrombosis and haemostasis 2013; 110(6): 1087–107.
(check this in PDF content)
7
Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circulation Cardiovascular quality and outcomes, 2008; 1(2): 84–91.
(check this in PDF content)
8
Gallego P, Roldan V, Marin F, et al. SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation. Am J Med, 2014.
(check this in PDF content)
9
Azoulay L, Dell’Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. EurHeart J,2014; 35(28): 1881–7.
(check this in PDF content)
10
Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMETT2R2scoreto poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest, 2014.
(check this in PDF content)
11
S J. Connolly, JEikelboom, C Joyner, et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med, 2011; 364: 806–81.
(check this in PDF content)
12
L Wallentin L, RD. Lopes RD, M Hanna M et al. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation. Circulation., 2013; 127: 2166–2176.
(check this in PDF content)
13
Easton JD, Lopes RD, Bahit M, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. The Lancet Neurology, Volume 11, Issue 6, 503–511.
(check this in PDF content)
14
JH. Alexander, RD. Lopes, L Thomas et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, (2014), 35: 224–232.
(check this in PDF content)
15
Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Longterm Anticoagulation Therapy) trial analysis. Circulation, 2014; 129(9): 961–70.
(check this in PDF content)
16
Wang X, Tirucherai G, Hlgen A, et al. Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev. 2014; 1: 187. Abstract.
(check this in PDF content)
17
Инструкция по применению препарата ELIQUIS (США) http://packageinserts.bms.com/ pi/pi_eliquis.pdf
(check this in PDF content)
18
Langenberg M, Hellemons BS, van Ree JW, et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ,1996; 313(7071): 1534.
(check this in PDF content)
19
Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Annals of internal medicine, 2009; 151(5): 297–305.
(check this in PDF content)
20
Palareti G, Salomone L, Cavazza M, et al. Stroke/thromboembolism and intracranial hemorrhage in a ‘real world’ atrial fibrillation population: The CAFBO STUDY (Complications of Atrial Fibrillation in the BOlogna area). Chest, 2014.
(check this in PDF content)
21
Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med, 1999; 159(7): 677–85.
(check this in PDF content)
22
Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a metaanalysis of randomized trials. Journal of the American Geriatrics Society, 2014; 62(5): 857–64.
(check this in PDF content)
23
G Flaker, RD. Lopes, SM. Al-Khatib et al. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation. JACC, 2014, Vol. 63, No. 11, 2014: 1082–7.
(check this in PDF content)
24
Инструкция по применению препарата Eliquis, Великобритания. http://www.medicines.org.uk/ emc/medicine/27220/SPC/Eliquis+5+mg+film-coated+tablets.
(check this in PDF content)
25
Пресс-релиз Bristol-Myers Squibb и Pfizer от 17.07.2014 http:// news.bms.com/press-release/bristolmyers-squibb-and-pfizer-announce-enrollment-firstpatient-phase-iv-emanate-tri.
(check this in PDF content)
26
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/. American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation,2014; 130: e199— e267, doi:10.1161/CIR.0000000000000041.
(check this in PDF content)
27
Sardar, Partha et al. Meta-Analysis of Risk of Stroke or Transient Ischemic Attack WithDabigatran for Atrial Fibrillation Ablation. American Journal of Cardiology, Volume 113, Issue 7: 1173—1177.
(check this in PDF content)
28
Tomoyuki Nagao, YasuyaInden, Masayuki SHimano et al. Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation. PACE, 2015; 38:155–163.
(check this in PDF content)
29
https://clinicaltrials.gov/ct2/show/NCT02227550.
(check this in PDF content)
30
Task Force M, Lip GY, Windecker S, et al. Management of antithrombotic therapyin atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular
(check this in PDF content)
31
This article is protected by copyright. All rights reserved. Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J, 2014. doi:10.1093/eurheartj/ehu298.
(check this in PDF content)
32
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; 381: 1107–1115.
(check this in PDF content)
33
Слайды к докладу MarkCrowther на научной сессии Американского общества сердца 2014 г. «ANNEXA™-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors».
(check this in PDF content)
34
http://my.americanheart.org/idc/groups/ahamahpublic/@wcm/@sop/@scon/documents/downloadable/ucm_469639.pdf.
(check this in PDF content)
35
Пресс-релиз компаний Portola, Bristol-Myers Squibb и Pfizer от 17.04.2014. http:// news.bms.com/pressrelease/portola-bristol-myers-squibb-and-pfizerannounce-statistically-significant-results-fir.
(check this in PDF content)